p53 represents an attractive target for anti-cancer drug development since its WT activity is disturbed in almost all human cancers either directly by mutations in the TP53 gene or indirectly through altered expression of p53 negative and positive regulators, such as MDM2 and ARF, respectively (36). The gene discussed is MDM2; the disease is cancer.